Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| macrophage | 37 studies | 43% ± 19% | |
| classical monocyte | 24 studies | 33% ± 12% | |
| non-classical monocyte | 23 studies | 48% ± 13% | |
| monocyte | 18 studies | 37% ± 21% | |
| microglial cell | 16 studies | 65% ± 18% | |
| conventional dendritic cell | 14 studies | 29% ± 10% | |
| myeloid cell | 13 studies | 46% ± 18% | |
| dendritic cell | 13 studies | 33% ± 16% | |
| mast cell | 13 studies | 28% ± 8% | |
| neutrophil | 7 studies | 37% ± 26% | |
| alveolar macrophage | 7 studies | 46% ± 21% | |
| mononuclear phagocyte | 6 studies | 46% ± 18% | |
| platelet | 4 studies | 20% ± 6% | |
| leukocyte | 4 studies | 32% ± 23% | |
| intermediate monocyte | 4 studies | 50% ± 21% | |
| natural killer cell | 4 studies | 18% ± 2% | |
| hematopoietic stem cell | 4 studies | 20% ± 3% | |
| megakaryocyte | 3 studies | 52% ± 18% | |
| tissue-resident macrophage | 3 studies | 44% ± 11% | |
| megakaryocyte-erythroid progenitor cell | 3 studies | 34% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 676.18 | 89 / 89 | 93% | 13.99 | 836 / 901 |
| prostate | 95% | 711.95 | 233 / 245 | 98% | 12.50 | 490 / 502 |
| lung | 100% | 2669.03 | 577 / 578 | 92% | 11.72 | 1061 / 1155 |
| intestine | 92% | 673.01 | 886 / 966 | 94% | 15.96 | 497 / 527 |
| breast | 93% | 510.83 | 429 / 459 | 92% | 8.18 | 1032 / 1118 |
| stomach | 89% | 489.80 | 321 / 359 | 93% | 12.26 | 265 / 286 |
| bladder | 95% | 528.19 | 20 / 21 | 63% | 8.86 | 317 / 504 |
| brain | 55% | 286.84 | 1451 / 2642 | 96% | 15.60 | 676 / 705 |
| esophagus | 88% | 403.70 | 1267 / 1445 | 63% | 4.50 | 115 / 183 |
| adrenal gland | 100% | 838.95 | 257 / 258 | 44% | 2.90 | 102 / 230 |
| uterus | 65% | 230.15 | 111 / 170 | 63% | 4.66 | 290 / 459 |
| pancreas | 36% | 132.61 | 118 / 328 | 92% | 17.11 | 164 / 178 |
| thymus | 53% | 194.80 | 347 / 653 | 67% | 5.64 | 405 / 605 |
| skin | 37% | 113.69 | 663 / 1809 | 83% | 12.61 | 393 / 472 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 13.82 | 29 / 29 |
| spleen | 100% | 6032.76 | 241 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 99% | 9831.32 | 920 / 929 | 0% | 0 | 0 / 0 |
| ovary | 42% | 147.36 | 75 / 180 | 57% | 3.71 | 246 / 430 |
| adipose | 98% | 965.01 | 1179 / 1204 | 0% | 0 | 0 / 0 |
| liver | 58% | 241.20 | 130 / 226 | 39% | 2.73 | 159 / 406 |
| blood vessel | 82% | 540.42 | 1101 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 78% | 5.71 | 35 / 45 |
| heart | 48% | 172.91 | 409 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 38% | 2.31 | 30 / 80 |
| muscle | 5% | 12.30 | 40 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006690 | Biological process | icosanoid metabolic process |
| GO_0045907 | Biological process | positive regulation of vasoconstriction |
| GO_0019371 | Biological process | cyclooxygenase pathway |
| GO_0030644 | Biological process | intracellular chloride ion homeostasis |
| GO_0070542 | Biological process | response to fatty acid |
| GO_0045471 | Biological process | response to ethanol |
| GO_0001516 | Biological process | prostaglandin biosynthetic process |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005829 | Cellular component | cytosol |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0004497 | Molecular function | monooxygenase activity |
| GO_0004796 | Molecular function | thromboxane-A synthase activity |
| GO_0005506 | Molecular function | iron ion binding |
| GO_0016705 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen |
| GO_0020037 | Molecular function | heme binding |
| GO_0036134 | Molecular function | 12-hydroxyheptadecatrienoic acid synthase activity |
| GO_0106256 | Molecular function | hydroperoxy icosatetraenoate dehydratase activity |
| Gene name | TBXAS1 |
| Protein name | Thromboxane A synthase 1 Thromboxane-A synthase (TXA synthase) (TXS) (EC 5.3.99.5) (Cytochrome P450 5A1) (Hydroperoxy icosatetraenoate dehydratase) (EC 4.2.1.152) Thromboxane-A synthase (EC 5.3.99.5) (Cytochrome P450 5A1) |
| Synonyms | TXAS CYP5 CYP5A1 |
| Description | FUNCTION: Catalyzes the conversion of prostaglandin H2 (PGH2) to thromboxane A2 (TXA2), a potent inducer of blood vessel constriction and platelet aggregation . Cleaves also PGH2 to 12-hydroxy-heptadecatrienoicacid (12-HHT) and malondialdehyde, which is known to act as a mediator of DNA damage. 12-HHT and malondialdehyde are formed stoichiometrically in the same amounts as TXA2 . Additionally, displays dehydratase activity, toward (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate (15(S)-HPETE) producing 15-KETE and 15-HETE . . |
| Accessions | ENST00000411653.6 [P24557-4] ENST00000458722.6 [P24557-3] F8WC80 A0A498U6I9 P24557 C9JS68 ENST00000425687.5 [P24557-2] ENST00000448866.7 [P24557-1] ENST00000422328.6 Q86UL7 F8WD37 Q9UDV3 ENST00000438104.6 ENST00000455353.6 ENST00000336425.10 [P24557-1] ENST00000414041.2 |